File

- Pandora Marketing LLC Continues to Serve Customers During Voluntary Chapter 11 Reorganization -

Retrieved on: 
Tuesday, February 27, 2024

During this transition, Pandora Marketing will continue its commitment to customers with their timeshare exit goals despite major developers continuing to attempt to stop Pandora's efforts to help clients.

Key Points: 
  • During this transition, Pandora Marketing will continue its commitment to customers with their timeshare exit goals despite major developers continuing to attempt to stop Pandora's efforts to help clients.
  • In October 2023, Pandora succeeded in decreasing a $1.5 million federal lawsuit by large developer Bluegreen to only $100,000 and achieved relief for 800 clients from their timeshare burden.
  • Through this filing, Pandora Marketing intends to safeguard its business, customers, employees, and goodwill while improving its business practices through reorganization and assessment within all departments.
  • Pandora is advised in this matter by Seth Shumaker, Attorney at Law, senior bankruptcy advisor.

Norfolk Southern files preliminary proxy statement, recommends shareholders vote for its director nominees

Retrieved on: 
Monday, February 26, 2024

ATLANTA, Feb. 26, 2024 /PRNewswire/ -- Norfolk Southern Corporation (NYSE: NSC) announced Monday that it has filed its preliminary proxy materials with the Securities and Exchange Commission (SEC) in connection with its upcoming 2024 Annual Meeting of Shareholders. The preliminary proxy statement is available on the Investor Relations section of the Norfolk Southern website at www.norfolksouthern.com. In connection with the filing, the Norfolk Southern Board of Directors:

Key Points: 
  • The preliminary proxy statement is available on the Investor Relations section of the Norfolk Southern website at www.norfolksouthern.com .
  • As noted in the preliminary proxy materials, the board unanimously recommends that shareholders vote on the WHITE card only for its slate of 13 directors.
  • Your vote FOR all 13 Norfolk Southern director nominees on the WHITE card will be critical.
  • In the interim, Norfolk Southern strongly urges shareholders to simply discard and NOT vote using any blue proxy card sent by Ancora.

ZK International Receives Nasdaq Notices Regarding Listing Deficiency

Retrieved on: 
Thursday, February 22, 2024

Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price Requirement"), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive trading days.

Key Points: 
  • Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price Requirement"), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive trading days.
  • Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement.
  • The Company would then be entitled to appeal Nasdaq's determination to a Nasdaq Listing Qualifications Panel and request a hearing.
  • If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal that decision to a Nasdaq Listing Qualifications Panel and request a hearing.

Annual Financial Statements Update for the Year Ended October 31, 2023

Retrieved on: 
Wednesday, February 21, 2024

Under National Instrument 51-102, the Required Filings are required to be made not later than February 28, 2024 (the " Filing Deadline").

Key Points: 
  • Under National Instrument 51-102, the Required Filings are required to be made not later than February 28, 2024 (the " Filing Deadline").
  • The Company believes that this acquisition constitutes a major purchase of assets that must be reported in its financial statement in accordance with IAS 10.
  • The Company continues to work to complete the Company's annual financial statements, and expects to file the Required Filings by March 30, 2024, and will issue a news release once the Required Filings have been filed.
  • The Company's auditors have also made significant efforts to complete its audit of the annual financial statements.

Statement from the Taxpayers' Ombudsperson about the launch of the 2024 tax season

Retrieved on: 
Wednesday, February 21, 2024

This year, the process of filing an income tax and benefit return may feel particularly daunting.

Key Points: 
  • This year, the process of filing an income tax and benefit return may feel particularly daunting.
  • Tax season can feel stressful, but you have the right to fair treatment from the CRA.
  • The Taxpayers' Ombudsperson assists, advises and informs the Minister of National Revenue about matters relating to services provided by the CRA.
  • The Ombudsperson ensures, in particular, that the CRA respects eight of the service rights outlined in the Taxpayer Bill of Rights.

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, February 16, 2024

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares, at a price to the public of $20.00 per share.

Key Points: 
  • Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares, at a price to the public of $20.00 per share.
  • The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, are $230.0 million.
  • All of the shares in the offering were sold by Immunome.
  • J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities acted as joint book-running managers for the offering.

Unusual Machines Announces Closing of $5,000,000 Initial Public Offering

Retrieved on: 
Friday, February 16, 2024

SAN JUAN, Puerto Rico, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Unusual Machines, Inc. (“Unusual Machines” or the “Company”), an emerging leader in first-person view (FPV) drone technology, announced today the closing of its initial public offering (the “Offering”) of 1,250,000 shares of common stock at a public offering price of $4.00 per share.

Key Points: 
  • SAN JUAN, Puerto Rico, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Unusual Machines, Inc. (“Unusual Machines” or the “Company”), an emerging leader in first-person view (FPV) drone technology, announced today the closing of its initial public offering (the “Offering”) of 1,250,000 shares of common stock at a public offering price of $4.00 per share.
  • The Company expects to receive aggregate gross proceeds of $5.0 million from the Offering, before deducting underwriting discounts and other related expenses.
  • The Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 common shares at the public offering price (the “Over-allotment Option”), less underwriting discounts.
  • acted as U.S. counsel to the Company and Sichenzia Ross Ference Carmel LLP acted as U.S. counsel to the Underwriters in connection with the Offering.

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

Retrieved on: 
Friday, February 16, 2024

These amended financial statements will have no impact on the Company’s cash, cash equivalents and marketable investments, cash runway or business operations.

Key Points: 
  • These amended financial statements will have no impact on the Company’s cash, cash equivalents and marketable investments, cash runway or business operations.
  • The Company is also reiterating its previous guidance that it has sufficient financial resources to fund its operations into 2026.
  • The Company, as a non-accelerated filer, remains on track for the timing of its next quarterly update and intends to file the amended financial statements as soon as feasible, targeting on or before March 14, 2024 for such filing and to report fourth quarter and full year 2023 results.
  • Additional information relating to these amended statements is available in the Company's Form 8-K filed today.

GE HealthCare Technologies Inc. Prices Secondary Offering of 13,000,000 Shares

Retrieved on: 
Friday, February 16, 2024

GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $82.25 per share ($80.605 per share, net of underwriting discount).

Key Points: 
  • GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $82.25 per share ($80.605 per share, net of underwriting discount).
  • GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).
  • Prior to the closing of the Offering, General Electric Company (“GE”) is expected to exchange the GEHC Shares for indebtedness of GE held by Morgan Stanley Senior Funding, Inc. and Morgan Stanley Bank, N.A.
  • The selling stockholder in the Offering has granted the underwriters an option to purchase additional shares of GE HealthCare common stock at the public offering price less the underwriting discount for 30 days.

GE HealthCare Technologies Inc. Commences Secondary Offering of 13,000,000 Shares

Retrieved on: 
Thursday, February 15, 2024

Prior to the closing of the Offering, General Electric Company (“GE”) is expected to exchange the GEHC Shares for indebtedness of GE held by Morgan Stanley Senior Funding, Inc. and Morgan Stanley Bank, N.A.

Key Points: 
  • Prior to the closing of the Offering, General Electric Company (“GE”) is expected to exchange the GEHC Shares for indebtedness of GE held by Morgan Stanley Senior Funding, Inc. and Morgan Stanley Bank, N.A.
  • (together, the “MS Lenders”), affiliates of Morgan Stanley & Co. LLC, the selling stockholder in the Offering by designation of the MS Lenders.
  • Following the debt-for-equity exchange, if consummated, Morgan Stanley & Co. LLC, as the selling stockholder in the Offering, intends to sell the GEHC Shares to the underwriters in the Offering.
  • The selling stockholder in the Offering has granted the underwriters an option to purchase additional shares of GE HealthCare common stock at the public offering price less the underwriting discount for 30 days.